Bio-Rad reports third-quarter 2026 financial results

ITEM 2.02 Results of Operations and Financial Condition

On November 4, 2026, Bio-Rad Laboratories, Inc. (the "Company") announced its financial results for the quarter ended September 30, 2026.¹ A copy of the press release is furnished as Exhibit 99.1 to this report.²

The information set forth under Item 7.01, Regulation FD Disclosure, concerning the Supplemental Earnings Presentation (as defined therein) is incorporated herein by reference.

ITEM 7.01 Regulation FD Disclosure

Also on November 4, 2026, the Company posted supplemental earnings materials with respect to its financial results for the quarter ended September 30, 2026 to its website (the "Supplemental Earnings Presentation")³, which can be accessed at www.bio-rad.com in the Investor Relations section under the subheading "Events & Presentations". A copy of the Supplemental Earnings Presentation is furnished as Exhibit 99.2 to this report.³

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1 and Exhibit 99.2 attached hereto, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended⁴ (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

ITEM 9.01 Financial Statements and Exhibits

Exhibit

Number Description

104.1 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIO-RAD LABORATORIES, INC.

Date: November 4, 2026 By: /s/ Roop K. Lakkaraju

Roop K. Lakkaraju

Executive Vice President, Chief Financial Officer

Press Release

Bio-Rad Reports Third -Quarter 2026 Financial Results

HERCULES, Calif.—November 4, 2026 -- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the third quarter ended September 30, 2026.

Norman Schwartz, Bio-Rad's Chief Executive Officer, stated: "Our third-quarter results reflect the steady progress we have been driving. We returned to currency-neutral revenue growth, led by Clinical Diagnostics and strong demand for our Droplet Digital™ PCR instruments. Excluding restructuring and impairment items, margins expanded, reflecting benefits of our transformation initiatives. The reprioritization of our R&D efforts is yielding new, differentiated products for our customers, and our progress gives us confidence in our 2026 outlook."

Financial Results Highlights

(In millions, except per share data and percentages)

GAAP Results

Income (loss) per diluted share $ 17.02 $ (12.70)

Net cash from operations $ 96.4 $ 120.9

Non-GAAP Results

The non-GAAP financial measures shown in the table above and discussed below exclude certain items detailed later in this press release under the heading "Use of Non-GAAP Reporting". A reconciliation between historical GAAP operating results and non-GAAP operating results is provided following the financial statements that are part of this press release.

Third -Quarter 2026 Results

Third-quarter 2026 total net sales were $656.4 million compared to $653.0 million reported for the third quarter of 2025, an increase of 0.5%.⁵ On a currency-neutral basis, sales increased 0.7 percent compared to the same period in 2025, driven by higher sales in Clinical Diagnostics segment.

Life Science segment net sales for the third quarter were $254.6 million⁶, a decrease of 2.8 percent compared to the same period in 2025. On a currency-neutral basis, Life Science segment sales decreased 2.4 percent compared to the 1 same period in 2025. The currency-neutral year-over-year sales decrease was primarily driven by lower process chromatography sales and ongoing challenges in the academic research market partially offset by increased Droplet Digital™ PCR sales.

Clinical Diagnostics segment net sales for the third quarter were $401.8 million⁶, an increase of 2.7 percent compared to the same period in 2025. On a currency-neutral basis, Clinical Diagnostics segment sales increased 2.8 percent compared to the same period in 2025. The currency-neutral year-over-year sales increase was primarily driven by growth in quality systems and diabetes products.

During the third quarter of 2026, the Company recognized a change in the fair market value of its investment in Sartorius AG, which substantially contributed to a ⁸net income of $458.6 million, or $17.02 per share, on a diluted basis, compared to a net loss of $(341.9) million, or $(12.70) per share, on a diluted basis⁷, reported for the same period in 2025.

The effective tax rate for the third quarter of 2026 was 14.9 percent, compared to 20.7 percent for the same period in 2025. The effective tax rate reported in these periods was primarily affected by the change in fair market value of our equity securities, shifts in the geographical mix of earnings, and release of valuation allowance established with respect to our deferred tax assets.

The non-GAAP effective tax rate for the third quarter of 2026 was 21.4 percent, compared to 26.7 percent for the same period in 2025. The lower rate in 2026 was driven by geographical mix of earnings.

Full-Year 2026 Financial Outlook

For the full-year 2026, the Company continues to expect non-GAAP, currency-neutral revenue to be in the range of a decline of approximately 3.0 percent to growth of approximately 0.5 percent¹⁰, and an estimated non-GAAP operating margin of approximately 10.0 to 12.0 percent.¹¹

Conference Call and Webcast

Management will discuss the Company's third quarter 2026 results and financial outlook in a conference call scheduled for 2:00 PM Pacific Time (5:00 PM Eastern Time) on November 4, 2026. To participate, dial (800) 715-9871 within the U.S., or (+1) (646) 307-1963 from outside the U.S., and provide access code: 9562470.

A live webcast of the conference call will also be available in the "Investor Relations" section of the Company's website under "Events & Presentations" at investors.bio-rad.com. A replay of the webcast will be available for up to a year.

BIO-RAD and Droplet Digital PCR are trademarks of Bio-Rad Laboratories, Inc.

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations wit